Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SLC25A16



This biomarker is also known as:
  • hML7,
  • Graves disease autoantigen,
  • solute carrier family 25 member 16,
  • ML7,
  • graves disease carrier protein,
  • Mitochondrial solute carrier protein homolog,
  • graves disease autoantigen,
  • GDA,
  • HGT.1,
  • mitochondrial solute carrier protein homolog,
  • GDC,
  • D10S105E,
  • Solute carrier family 25 member 16,
  • solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16,

View in BioMuta


SLC25A16 is a member of the mitochondrial carrier family and contains three tandemly repeated mitochondrial carrier protein domains. The SLC26A16 protein is found in the inner membrane of the mitochondria where it is necessary for the accumulation of coenzyme A in the mitochondrial matrix. SLC25A16 also facilitates the rapid transport and exchange of molecules between the cytosol and the mitochondrial matrix space. The SLC25A16 gene is thought to be involved in Graves' disease.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: SLC25A16


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

ADH5 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.